Motif Neurotech, a developer of brain stimulation devices for depression, raised $18.75 million in Series A funding, CEO Jacob Robinson tells Axios exclusively.
Why it matters: The most widely-available depression treatment is selective serotonin re-uptake inhibitors (SSRIs), but as many as one-third of people don't respond to the drugs. For them, there's hope that electronic stimulation can help.
